Lineage Cell Therapeutics (LCTX) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Q1 2026 results due Tuesday, May 12 after the market close with analysts modeling ($0.02) EPS and $4.801M in revenue; the earnings call is scheduled for 4:30 PM ET.
• Wall Street has a consensus "Buy" rating on LCTX with an average price target of $6.25, and several firms (including Canaccord and HC Wainwright) have issued buy ratings and targets as high as $9.00.
• Shares recently traded up 4.6% to $1.49 (market cap ~$370M) and are 62.47% institutionally owned; LCTX also topped prior-quarter estimates with $0.00 EPS vs. a -$0.07 consensus and $6.61M in revenue.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) is expected to be announcing its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $4.8010 million for the quarter. Investors are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.00 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.07. Lineage Cell Therapeutics had a negative net margin of 436.47% and a negative return on equity of 76.13%. The business had revenue of $6.61 million for the quarter, compared to the consensus estimate of $1.96 million. On average, analysts expect Lineage Cell Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lineage Cell Therapeutics Stock Up 4.6%

LCTX traded up $0.07 during trading on Tuesday, hitting $1.49. The company's stock had a trading volume of 568,296 shares, compared to its average volume of 1,161,428. Lineage Cell Therapeutics has a one year low of $0.43 and a one year high of $2.09. The firm has a market cap of $370.21 million, a PE ratio of -5.30 and a beta of 1.60. The business's 50 day simple moving average is $1.64 and its 200-day simple moving average is $1.69.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on LCTX shares. Canaccord Genuity Group started coverage on shares of Lineage Cell Therapeutics in a research report on Tuesday, April 28th. They issued a "buy" rating and a $9.00 price target on the stock. D. Boral Capital reiterated a "buy" rating and issued a $3.00 price target on shares of Lineage Cell Therapeutics in a research report on Monday. HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 24th. Finally, B. Riley Financial increased their price target on shares of Lineage Cell Therapeutics from $3.00 to $4.00 and gave the stock a "buy" rating in a research report on Wednesday, March 25th. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $6.25.

Institutional Trading of Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of LCTX. Royal Bank of Canada raised its position in shares of Lineage Cell Therapeutics by 1,578.9% during the 1st quarter. Royal Bank of Canada now owns 528,656 shares of the company's stock valued at $237,000 after purchasing an additional 497,168 shares during the period. Rhumbline Advisers raised its position in shares of Lineage Cell Therapeutics by 9.9% during the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company's stock valued at $91,000 after purchasing an additional 18,092 shares during the period. XTX Topco Ltd raised its position in shares of Lineage Cell Therapeutics by 117.8% during the 2nd quarter. XTX Topco Ltd now owns 94,054 shares of the company's stock valued at $85,000 after purchasing an additional 50,876 shares during the period. Jump Financial LLC bought a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter valued at $28,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter valued at $69,000. 62.47% of the stock is currently owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.